Completed PHASE4 INTERVENTIONAL 2-arm NCT02626494

Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction (CoGlu)

Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction: The Role of Glutamate

Sponsor: Max-Planck-Institut Tübingen

Updated 6 times since 2017 Last updated: Apr 28, 2017 Started: Mar 31, 2015 Primary completion: Mar 31, 2017 Completion: Mar 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Cocaine Addiction and is currently completed. Max-Planck-Institut Tübingen leads this study, which shows 6 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jun 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Jun 2017 [monthly]

Recruiting PHASE4

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Max-Planck-Institut Tübingen
Psychiatric University Hospital, Zurich
Swiss Federal Institute of Technology
Zurich Center for Integrative Human Physiology

Data source: Psychiatric University Hospital, Zurich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zurich, Switzerland